Image For Activity Cover
Treatment of Opioid Use Disorder in the Emergency Department: Should it be a Choice?
Gail D’Onofrio, MD, Professor and Chair, Department of Emergency Medicine, Yale University School of Medicine
Target Audience
Physicians, nurse practitioners or other advanced practice nurses, PAs, and pharmacists.
Credit Designations Available
AMA PRA Category 1 Credit™, Nursing Contact Hours, AAPA Category 1 CME credit, and Pharmacy CE credit.
Module Description
This webinar will focus on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. Gail D’Onofrio, MD, will discuss her pioneering work in creating the evidence for initiating ED buprenorphine treatment with ED patients presenting with opioid use disorder. Overall, the opioid epidemic intertwined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with the rising rate of fentanyl use. Data supporting the use of buprenorphine in the ED setting as well as the consequences of not initiating treatment will be discussed. While the use of ED prescribed buprenorphine has increased, universal adoption has lagged. Barriers to implementation of ED buprenorphine will be discussed as well as strategies to overcome these challenges. Components of successful integration of an ED program with community partnerships will be outlined. Current research by emergency physicians regarding innovative strategies such as high-dose buprenorphine inductions and use of extended release 7-day formulation of buprenorphine will be discussed. Initiation of buprenorphine effectively reduces withdrawal symptoms, improves adherence to treatment, and saves lives.
Educational Objectives
  • Evaluate outcomes for Opioid Use Disorder in patients receiving buprenorphine through the Emergency Department and discuss supporting evidence
  • Identify barriers and solutions to initiating buprenorphine in the Emergency Department
  • Apply harm reduction strategies and components of the buprenorphine integration pathway
  • Utilize the Brief Negotiation Interview, an evidence-based intervention to increase consent with Opioid Use Disorder treatment
  • Discuss innovative solutions for buprenorphine induction in the ED including different formulations of buprenorphine and high dose strategies
Method of participating in the learning process

In order to receive maximum credit, learners must: 

1. Review the materials provided.
2. Complete knowledge-based assessment questions to assess both prior knowledge and knowledge change following the activity
3. Complete an evaluation to assess satisfaction and plans for individual and/or team practice change.
4. Follow instructions at the end of the course regarding how to retrieve a certificate.* 

*Credit will not be awarded unless all components of the program are completed.  Partial credit will not be awarded.

Availability: On-Demand
Expires on 05/10/2024
Cost: FREE
Credit Offered:
1 CME Credit
1 PA-CME Credit
1 Other Professionals Credit
1 Nursing Credit
1 Pharmacy Credit
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.

Funding for this initiative was made possible (in part) by grant nos. 1H79TI086770 and 1H79TI085588 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

For Buprenorphine Training Inquiries, email PCSS-MOUD.


Powered By